BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

HIV Clinical Trial

— BATAR  

Official title:

A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00931801
• Other study ID #: 09-102
• Status: Completed
• Phase: Phase 4
• First received: June 30, 2009
• Last updated: July 18, 2017
• Start date: December 2009
• Est. completion date: March 2012

Study information

• Verified date: July 2017
• Source: Community Research Initiative of New England
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase IV pilot study is to evaluate the safety, tolerability, and satisfaction of a nucleoside analog reverse-transcriptase inhibitors (NRTI)sparing regimen for participants fully suppressed on an atazanavir/ritonavir based highly active antiretroviral therapy (HAART)regimen plus emtricitabine/tenofovir (Truvada). Several pharmacologic factors support this concept including the favorable drug interaction between atazanavir and raltegravir. Participants will be randomized to either continue on their current regimen or one of two study arms (atazanavir 300mg plus ritonavir 100mg daily plus raltegravir 400mg twice daily or atazanavir 300mg twice daily plus raltegravir 400mg twice daily). Participants will be followed for 48 weeks for safety, tolerability, and satisfaction. After baseline, the participants will have six clinic visits for evaluation and labs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: March 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection

• Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screening

• No plan to make changes to HIV treatment regimen (other than those required by the study) in the next 48 weeks

• Undetectable HIV RNA at screening AND no HIV RNA>200 copies during the 180 day period prior to screening

• CD4 count>200

• No evidence of resistance to any of the drugs in any of the 3 arms, if prior resistance tests are available

• Subjects who, in the opinion of their treating physicians, would be candidates to switch antiretroviral medications

• Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of study drug

• Ability and willingness to provide written informed consent and comply with protocol requirements

Exclusion Criteria:

• Prior exposure to raltegravir or elvitegravir

• Women who are pregnant, breast-feeding, or with a positive pregnancy test

• Sexually active fertile men not using effective birth control if their female partners are of child-bearing potential

• Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of study drug

• Life expectancy less than 6 months

• Presence of any currently active AIDS defining conditions with the exception of stable cutaneous Kaposi's sarcoma

• Treatment with proton-pump inhibitor or H2-receptor antagonist

• ECG demonstrating atrioventricular block, prolonged QRS interval greater than 12 ms, or known complete bundle branch block

• Acute or chronic hepatitis B infection as evidenced by presence of hepatitis B surface antigen and absence of hepatitis B surface antibody

• Clinical or laboratory evidence of significantly decreased hepatic function of decompensation irrespective of liver enzyme levels

• Prisoners or subjects who are involuntarily incarcerated

• Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• atazanavir/raltegravir
Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
• atazanavir/raltegravir
Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
• atazanavir/tenofovir/emtricitabine
Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine

Locations

Country	Name	City	State
United States	Community Research Initiative of New England - Boston	Boston	Massachusetts
United States	David M. Lee, MD, PA d/b/a/ Uptown Physicians' Group	Dallas	Texas
United States	Denver Public Health	Denver	Colorado
United States	AIDS Healthcare Foundation	Los Angeles	California
United States	Orlando Immunology Center	Orlando	Florida
United States	Spectrum Medical Group	Phoenix	Arizona
United States	Treasure Coast Infectious Disease Consultants	Vero Beach	Florida
United States	Whitman-Walker Clinic	Washington, D.C.	District of Columbia
United States	Christi Research	Wichita	Kansas

Sponsors (3)

Lead Sponsor	Collaborator
Community Research Initiative of New England	Bristol-Myers Squibb, Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maintenance of Virologic Suppression	To evaluate and compare maintenance of virologic suppression with raltegravir (RAL) 400mg 2x daily plus atazanavir (ATV) dosed either as ATV/ritonavir (RTV)300/100mg 1x daily or ATV 300mg 2x daily in subjects with virologic suppression on a standard regimen of ATV/RTV plus Truvada. Virologic suppression is defined as HIV RNA < 40 copies/mL.	48 weeks
Secondary	The Difference in CD4 From Baseline to Week 48	Change in mean CD4 from Baseline to Week 48.	Baseline and Week 48
Secondary	The Change in Adherence to Study Treatment Arm From Baseline to Week 48	Adherence to study treatment reported as the percentage of doses of the prescribed treatment arm regimen taken, described by each subject through recall of dosing in the three days prior to the visit Baseline and Week 48 vistis. The change in adherence is reflected as the difference of the mean percentage of adherence per arm between Baseline and Week 48 visits.	Baseline and Week 48
Secondary	Change in Quality of Life From Baseline to 48 Weeks of Study Treatment	Quality of Life was measured by self report using a standardized scale, where 0 is death and 100 is perfect health. The baseline measure was obtained prior to initiation of study treatment arm. The week 48 measure captures Quality of Life by self report at 48 weeks of study treatment.	baseline and 48 weeks